Terminated trial tests new prep for 'Living Drug' against tough lymphoma
NCT ID NCT05714345
Summary
This study aimed to see if adding a new drug (ALLO-647) to the standard preparation regimen before a CAR T-cell therapy (ALLO-501A) was more effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. It compared the new combination against the standard preparation to see which led to better disease control and safety. The trial was terminated early, enrolling only 2 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Universitair Ziekenhuis Brussel
Brussels, 1090, Belgium
-
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky, 40202, United States
Conditions
Explore the condition pages connected to this study.